January 31, 2013
PET/CT results can predict which patients will respond to high-dose-rate endorectal brachytherapy for stage II and III rectal cancer, according to a study presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. The results could pave the way for easier treatments and better outcomes.
Neoadjuvant chemoradiation followed by surgery is the standard of care for patients with rectal adenocarcinoma. But researchers at John Hopkins University are looking at the use of high-dose-rate endorectal brachytherapy (ENDO-HDR) in select patients to see if it might allow them to skip the chemotherapy, proceed to surgery after a few rounds of ENDO-HDR, and hopefully live out their lives in health.